SuperGen to Present at BioEquity Europe on May 23rd & 24th
16 Maio 2011 - 9:00AM
Business Wire
SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated
to the discovery and development of novel cancer therapies, today
announced that James S.J. Manuso, Ph.D., president and chief
executive officer, will present at BioEquity Europe 2011 on Monday
and Tuesday, May 23rd and 24th in Paris.
SuperGen's corporate presentation will take place on May 23 at
11:00 a.m. CEST. In addition, Dr. Manuso will participate in a
panel discussion titled, “Strategy: Squaring the Circle” about
building companies to study disease biology based on platform
technology, on May 24 at 1:45 p.m. CEST. More information on the
panel can be found at http://www.biocentury.com/Conferences.
About SuperGen
SuperGen is a pharmaceutical company dedicated to discovery and
development of novel cancer therapeutics in epigenetic and cell
signaling modulation. The Company develops products through
biochemical and clinical proof of concept to partner for further
development and commercialization. On April 6, 2011, SuperGen
entered into a definitive merger agreement to acquire Astex
Therapeutics Limited, a UK based biotechnology company. The
transaction is subject to customary regulatory, legal and
shareholder approvals. For more information about SuperGen, please
visit http://www.supergen.com.
Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Supergen, Inc. (MM) (NASDAQ:SUPG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Supergen, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de SuperGen, Inc.